Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Craif to Use $33M Financing to Support US Clinical Trial for Urine-Based Pancreatic Cancer Test

19 August 2026 · By · Wire by Fusion42

Published

19 August 2026

Topic

opportunities

◆ Sectors

Diagnostics

◆ Geography

United States

◆ Source

Read at genomeweb.com →

◆ Verified

Fusion42 · 19 August 2026 · Fusion42 review

Craif has secured $33 million in financing to advance a US clinical trial for its urine-based pancreatic cancer test, marking a significant development in non-invasive cancer diagnostics.

This Wire brief sits within Fusion42's coverage of Diagnostics.

◆ ◆ The Wire takeaway

Your biotech startup can now explore urine-based cancer diagnostics with backed clinical validation underway; clinical trial financing opens a door to faster US market entry.

◆ Coverage

1 source · 19 Aug 2026

◆ Related on Wire

◆ Topics

Diagnosticsclinical-trialcancer-diagnosticsnon-invasive-testfundingpancreatic-cancer